For example, in gynaecological cancers, the PARPi olaparib is approved for use as a maintenance treatment for advanced cancer patients with deleterious or suspected germline or somatic BRCA1/2‐mutations who have shown a prior response to first‐line platinum‐based chemotherapy (a clinical indication that HR is defective) [14]. This evidence concerns the gene BRCA1 and cancer.